Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment…
<!-- Name:DistributionId Value:8782751 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Adial Pharmaceuticals
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to…
<!-- Name:DistributionId Value:8740296 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a…
CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary…
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s…
CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary…
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in…
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from…
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
CHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on…
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of…
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company…
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on…
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a…
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today…
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug…
CHARLOTTESVILLE, Va., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on…